Spring Creek Capital’s TriSalus Life Sciences Warrant TLSIW Stock Holding History

Spring Creek Capital’s Portfolio TLSIW Stock Details TLSIW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-167,566	Closed	-$42K	–	69
2022 Q1	$42K	Hold	167,566	–	–	﹤0.01%	592
2021 Q4	$87K	Hold	167,566	–	–	﹤0.01%	483
2021 Q3	$137K	Hold	167,566	–	–	0.01%	370
2021 Q2	$171K	Buy	167,566 +900	+0.5%	+$888	0.01%	364
2021 Q1	$183K	Buy	+166,666	New	+$301K	0.01%	321

Other funds holding TLSIW

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return

Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Islet Management New York $49.1M AUM 17.59% 1-Year Est. Return

KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

Spring Creek Capital's TLSIW Position: Q2 2022 in Review

Spring Creek Capital sold out of TriSalus Life Sciences Warrant (TLSIW) in Q2 2022, closing a stake of 167,566 shares — an estimated $42K sold.

Spring Creek Capital first reported a position in TLSIW in Q1 2021 and held it in 5 quarters. The position peaked at $183K in Q1 2021. 30 funds tracked by Wall St. Rank hold TLSIW as of Q2 2022.

Spring Creek Capital reported no remaining TriSalus Life Sciences Warrant position as of Q2 2022 after selling out during the quarter.
Spring Creek Capital sold 167,566 TriSalus Life Sciences Warrant shares in Q2 2022, an estimated $42K.
Spring Creek Capital first reported a position in TriSalus Life Sciences Warrant in Q1 2021 and held it in 5 quarters.
Spring Creek Capital's TriSalus Life Sciences Warrant position peaked at $183K in Q1 2021.
30 funds tracked by Wall St. Rank held TriSalus Life Sciences Warrant as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.